577-85-5Relevant articles and documents
Transient Absorption Study of the Intramolecular Excited-State and Ground-State Proton Transfer in 3-Hydroxyflavone and 3-Hydroxychromone
Itoh, Michiya,Tanimoto, Yoshifumi,Tokumura, Kunihiro
, p. 3339 - 3340 (1983)
-
Direct evidence of excited-state intramolecular proton transfer in 2'-hydroxychalcone and photooxygenation forming 3-hydroxyflavone
Chou,Matinez,Cooper
, p. 4943 - 4944 (1992)
-
Proton Transfer in Matrix-Isolated 3-Hydroxyflavone and 3-Hydroxyflavone Complexes
Brucker, G. A.,Kelley, D. F.
, p. 2856 - 2861 (1987)
The proton-transfer dynamics of 3-hydroxyflavone (3HF) and 3HF-solvent complexes have been studied in 10 K argon matrices.Both static and picosecond fluorescence spectroscopies were used.The results indicate that proton transfer in bare molecules occurs quite rapidly (10 ps).The 3HF-solvent complexes are formed by codeposition of argon:solvent mixtures (typically 2000:1) with 3HF followed by matrix annealing.Solvents include water, methanol, ethanol, and diethyl ether.The results show that proton transfer is very fast (10 ps) in alkohol and water monosolvates and can be interpreted in terms of cyclically hydrogen-bonded structures.The results also show that the diethyl ether monosolvate undergoes proton transfer in about 40 ps.Solvation with two or more waters or alkohols was found to inhibit proton transfer.
Exploring 3-Benzyloxyflavones as new lead cholinesterase inhibitors: synthesis, structure–activity relationship and molecular modelling simulations
Mughal, Ehsan Ullah,Sadiq, Amina,Ayub, Momna,Naeem, Nafeesa,Javid, Asif,Sumrra, Sajjad Hussain,Zafar, Muhammad Naveed,Khan, Bilal Ahmad,Malik, Fouzia Perveen,Ahmed, Ishtiaq
, p. 6154 - 6167 (2020/08/10)
In this protocol, a series of 3-benzyloxyflavone derivatives have been designed, synthesized, characterized and investigated in?vitro as cholinesterase inhibitors. The findings showed that all the synthesized target compounds (1–10) are potent dual inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes with varying IC50 values. In comparison, they are more active against AChE than BChE. Remarkably, amongst the series, the compound 2 was identified as the most active inhibitor of both AChE (IC50 = 0.05 ± 0.01 μM) and BChE (IC50 = 0.09 ± 0.02 μM) relative to the standard Donepezil (IC50 = 0.09 ± 0.01 for AChE and 0.13 ± 0.04 μM for BChE). Moreover, the derivatives 5 (IC50 = 0.07 ± 0.02 μM) and 10 (0.08 ± 0.02 μM) exhibited the highest selective inhibition against AChE as compared to the standard. Preliminary structure-activity relationship was established and thus found that cholinesterase inhibitory activities of these compounds are highly dependent on the nature and position of various substituents on Ring-B of the 3-Benzyloxyflavone scaffolds. In order to find out the nature of binding interactions of the compounds and active sites of the enzymes, molecular docking studies were carried out. (Figure presented.) HIGHLIGHTS 3-benzyloxyflavone analogues were designed, synthesized and characterized. The target molecules (1–10) were evaluated for their inhibitory potential against AChE and BChE inhibitory activities. Limited structure-activity relationship was developed based on the different substituent patterns on aryl part. Molecular docking studies were conducted to correlate the in?vitro results and to identify possible mode of interactions at the active pocket site of the enzyme. Communicated by Ramaswamy H. Sarma.
Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers
Roy, Tithi,Boateng, Samuel T.,Banang-Mbeumi, Sergette,Singh, Pankaj K.,Basnet, Pratik,Chamcheu, Roxane-Cherille N.,Ladu, Federico,Chauvin, Isabel,Spiegelman, Vladimir S.,Hill, Ronald A.,Kousoulas, Konstantin G.,Nagalo, Bolni Marius,Walker, Anthony L.,Fotie, Jean,Murru, Siva,Sechi, Mario,Chamcheu, Jean Christopher
, (2021/01/14)
Due to hurdles, including resistance, adverse effects, and poor bioavailability, among others linked with existing therapies, there is an urgent unmet need to devise new, safe, and more effective treatment modalities for skin cancers. Herein, a series of flavonol-based derivatives of fisetin, a plant-based flavonoid identified as an anti-tumorigenic agent targeting the mammalian targets of rapamycin (mTOR)-regulated pathways, were synthesized and fully characterized. New potential inhibitors of receptor tyrosine kinases (c-KITs), cyclin-dependent kinase-2 (CDK2), and mTOR, representing attractive therapeutic targets for melanoma and non-melanoma skin cancers (NMSCs) treatment, were identified using inverse-docking, in vitro kinase activity and various cell-based anticancer screening assays. Eleven compounds exhibited significant inhibitory activities greater than the parent molecule against four human skin cancer cell lines, including melanoma (A375 and SK-Mel-28) and NMSCs (A431 and UWBCC1), with IC50 values ranging from 0.12 to 15 μM. Seven compounds were identified as potentially potent single, dual or multi-kinase c-KITs, CDK2, and mTOR kinase inhibitors after inverse-docking and screening against twelve known cancer targets, followed by kinase activity profiling. Moreover, the potent compound F20, and the multi-kinase F9 and F17 targeted compounds, markedly decreased scratch wound closure, colony formation, and heightened expression levels of key cancer-promoting pathway molecular targets c-Kit, CDK2, and mTOR. In addition, these compounds downregulated Bcl-2 levels and upregulated Bax and cleaved caspase-3/7/8 and PARP levels, thus inducing apoptosis of A375 and A431 cells in a dose-dependent manner. Overall, compounds F20, F9 and F17, were identified as promising c-Kit, CDK2 and mTOR inhibitors, worthy of further investigation as therapeutics, or as adjuvants to standard therapies for the control of melanoma and NMSCs.
